New Roche leukemia drug shows clear advantage over Rituxan: study

November 7, 2013 2:20 PM

23 0

New Roche leukemia drug shows clear advantage over Rituxan: study

(Reuters) - Roche's newly approved leukemia drug Gazyva helped patients live nearly a year longer without the disease worsening than the drugmaker's top-selling Rituxan in a head-to-head trial that should help fend off competition from cheaper versions of the older medicine.

Gazyva, previously known as GA101, was approved in the United States last week as an initial treatment for patients with chronic lymphocytic leukemia, or CLL, one of the most common forms of blood cancer. It is awaiting approval decisions in Europe and other markets.

Read more

To category page

Loading...